Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in adult ocular myasthenia gravis
CTR20262521Phase 3Active
- Sponsor
- UCB
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Sep 2026; status: active.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20262521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262521.